Chemistry data
- Class
- growth hormone secretagogue (GHS) / synthetic hexapeptide
- Molecular weight
- 887 g/mol
- Sequence
- His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2
- Half-life
- approximately 55-71 minutes
- Routes
- subcutaneous · intramuscular · intravenous
- Studied doses
- subcutaneous 200 mcg per injection, 1-3x daily · intravenous 0.5, 1, 2 mcg/kg bolus · subcutaneous 100-300 mcg/kg/day
Limitless Life Nootropics — Hexarelin
Compound15Affiliate link — we may earn a commission at no extra cost to you. Research compounds are for laboratory use only.
Growth hormone secretagogues are often judged by one thing: how much GH they release. Hexarelin fails that test in a very interesting way. Research suggests this synthetic hexapeptide triggers GH release like its peers. But it also binds CD36, a receptor on heart muscle cells that ghrelin never touches PMID: 10465272 . The result is a second story: heart effects that work on their own, away from the GH axis.
That dual identity came as a surprise. Hexarelin was built from GHRP-6
GHRP-6 growth hormone secretagogue (GHS) / ghrelin receptor agonist Ghrelin mimetic hexapeptide — strongest appetite stimulation among GHRPs with one amino acid swap (a 2-methyl-tryptophan swap at position 2). It was meant to be a more stable GH-releasing peptide. The unexpected heart findings made it something rarer. Now it is studied as a GH secretagogue and as a direct heart agent.
Preclinical data point to effects on muscle growth, fat use, heart function, and swelling [PMID: 7910650, 10465272, 12379504, 25645463]. By the end of this page you will know how both paths work, what the data show, where the dose data comes from, and why that chance heart find is the thread to follow.
Limitless Life Nootropics — Hexarelin
Compound15Affiliate link — we may earn a commission at no extra cost to you. Research compounds are for laboratory use only.
Regulatory Status
- United States
- Research use only
- European Union
- Research use only
- United Kingdom
- Research use only
What is this compound?
Hexarelin began as an upgrade try. Its parent, GHRP-6
GHRP-6 growth hormone secretagogue (GHS) / ghrelin receptor agonist Ghrelin mimetic hexapeptide — strongest appetite stimulation among GHRPs , was the first-generation growth hormone-releasing peptide. It worked but broke down fast in the body. So researchers swapped one part. They took out the tryptophan at spot 2 and put in a D-2-methyl-tryptophan piece. They got what they wanted: more body stability and stronger receptor grip. In human intravenous studies, the half-life was about 55 to 71 minutes, longer than GHRP-6. The end result, also called Examorelin, is a synthetic hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), weight 887 Da, formula C47H58N12O6.
The upgrade had a free extra. Like all growth hormone secretagogues, hexarelin starts the ghrelin receptor (GHSR-1a) on pituitary somatotrophs to set off growth hormone release PMID: 7957536 . But it also binds CD36, a class B scavenger receptor found on cardiomyocytes and other non-endocrine body parts PMID: 10465272 . Ghrelin — the body's own GHSR-1a ligand — does not bind CD36 in these parts. So hexarelin is different from both the natural hormone and its synthetic kin.
In research, the peptide is put in by shot under the skin, in the muscle, or in a vein. Its short half-life means the test plan must plan for quick clearance. Yet neither the preclinical animal work nor the limited human phase I data call this a barrier PMID: 7957536 . What these two receptors actually do, alone and maybe together, is where the story gets good.
How it works
Hexarelin works on two separate receptor systems. The gap between them explains nearly all that is good about this compound.
The first path is shared by all secretagogues. When hexarelin binds GHSR-1a on pituitary somatotrophs, it starts G-alpha-q/11 and G-alpha-i/o signal proteins. These set off phospholipase C (PLC), raise the calcium inside the cell, and push out stored growth hormone [PMID: 7910650, 7957536]. A dose test in healthy human volunteers backed this in humans: IV hexarelin at 0.5 to 2 mcg/kg gave a clear, dose-based rise in blood GH PMID: 7957536 .
Then comes the path none else use. CD36 — a scavenger receptor on cardiomyocytes, macrophages, and blood vessel walls — binds hexarelin but not ghrelin, and that grip starts protein kinase C (PKC) signal work and lifts L-type calcium flow in heart muscle cells. This makes a positive inotropic effect — more squeeze force — that works on its own from growth hormone PMID: 10465272 .
This GH-free heart care is the most-studied arm of hexarelin's work path. Work shows heart cells guard from cell death set off by angiotensin II, doxorubicin hurt, and blood cut-and-restore hurt [PMC4178518]. It also cuts heart scar through less collagen build and stops fibroblast growth. In plaque tests, hexarelin held back plaque and bettered the HDL-to-LDL mix [PMC4178518]. None of these heart effects come from GH rise. They rise from direct receptor grip in heart tissue.
The open call is how the two paths work when both run at once: as one boost, as added parts, or as side-by-side bits, by tissue spot and dose. That brings up the real next step: what has the work measured so far?
- GHSR-1a (ghrelin receptor) agonism - stimulates GH release from pituitary somatotrophs via G-alpha-q/11 and G-alpha-i/o, PLC, and Ca2+ cascade
- CD36 cardiac receptor binding - unique to hexarelin, mediates cardioprotective effects independent of growth hormone
- Positive inotropic effect via PKC signaling and L-type Ca2+ current enhancement
- Anti-apoptotic effects in cardiomyocytes - protects against angiotensin II, doxorubicin, and ischemia-reperfusion injury
- Anti-fibrotic activity - reduces collagen deposition and inhibits cardiac fibroblast proliferation
- Anti-atherosclerotic effects - suppresses plaque formation, improves HDL/LDL ratio
Research Findings
Start with the call that pulls most here: muscle. In baby and grown rat tests, hexarelin shot gave clear GH release, and the fall-out hit protein build and lean mass gain PMID: 7910650 . The link chain is known — growth hormone holds nitrogen, raises protein build rates, and drives muscle cell growth. Yet the data stops at preclinical: no fixed human tests have backed these muscle-building ends.
Where the work truly sets itself apart is heart. Unlike other GHS compounds whose heart work rides on GH rise, hexarelin works through direct CD36 grip PMID: 10465272 . In post-heart-attack tests, work showed better heart function — more ejection fraction, less scar, less bad build PMID: 10614623 — plus cell-death-hold, scar-cut, and plaque-hold traits in heart tissue [PMC4178518]. As these effects are GH-free, they last even when the GH axis is shut off. That matters a lot to any one studying heart care as such, not as a hormone by-product.
Body mix adds a quiet sign. Growth hormone steers fat break — the split of stored triglycerides — and lifts burn rate PMID: 12379504 . And animal tests hint hexarelin may push fat burn, though the size and steadiness of this call need more look. Preclinical anti-swell work rounds out the mix PMID: 25645463 .
Sleep pops up now and then in word-of-mouth tells, likely tied to growth hormone's own rise in deep sleep steps. No peer tests have run a set look at hexarelin's sleep work, so those stays as tales. The heart file, by contrast, keeps grow — which makes the safe picture the next call.
- muscle-growth preclinical
- cardiovascular-health preclinical
- fat-loss preclinical
- anti-inflammatory preclinical
Dosage Context Explained
Dose data for hexarelin comes from three very different hands — human phase IV needle shots, tales of self-shot under-skin use, and preclinical animal work — and they do not hold equal weight.
Take the hard one first: the dose test in healthy human volunteers gave IV bolus shots of 0.5, 1, and 2 mcg/kg and saw a clear, dose-based rise in blood growth hormone, with the top GH spike at 2 mcg/kg PMID: 7957536 . That set activity in humans at low mcg-per-kg doses — and no more. The test did not look at repeat shots, long-run ends, or under-skin use.
The tale tier tells of under-skin shots of 200 mcg each, given one to three times a day. These lack clinic back and set no real plan. One body fact holds true in all spots: the short half-life (~55–71 minutes) means the compound clears fast, a real think for shot-rate picks in test plans.
Animal tests have run 100 to 300 mcg/kg/day under skin PMID: 7910650 — numbers that do not pass straight, as species differ much in body work, receptor count, and burn rate. So plan setters face a field of marks, not rules. That puts the weight on what comes after the shot: the told effects, and their bounds.
-
- Administration Routes
- subcutaneous
- Range
- 200 mcg per injection, 1-3x daily
anecdotal human use
-
- Administration Routes
- intravenous
- Range
- 0.5, 1, 2 mcg/kg bolus
human phase I dose-response study
-
- Administration Routes
- subcutaneous
- Range
- 100-300 mcg/kg/day
animal studies
Reconstitution Calculator
Determine exactly how much bacteriostatic water to add and how many units to draw for your target dose.
Side Effects: Research Context
Honest tag first: hexarelin's told side-effect list comes from tale tells, limited human phase I data, and preclinical reads — not fixed clinical trials with set safe watch.
The top told effect is a short rise in hunger, and that is just what hitting the ghrelin receptor should do — it is the same receptor the body uses for hunger sign PMID: 7957536 . Tales also tell of mild head hurt, short red heat at the shot spot, and water hold at high doses. The last may tie to growth hormone's known salt-hold and water-balance work.
Theorized no-go spots match any GH-starting compound: active cancer, given growth hormone's role in cell growth, and too-much GH spots like acromegaly or gigantism. Then comes the hexarelin-only think — CD36. As long-run grip of this heart receptor looks like care in preclinical tests, the far-out ends of long-run CD36 shift in human heart tissue stay a blank.
Past these points, the far-out safe picture in humans is just no-mark. The lack of set data is not proof of safe; it is proof of too little look — which is why calling hexarelin a research-only compound fits rather than rings as filler. How rules tags it follows straight from that fact.
- transient increase in appetite (ghrelin receptor activation)
- mild headache (anecdotal)
- water retention at high doses (anecdotal)
- transient flushing post-injection (anecdotal)
Where to source
Research use only| Supplier | Commission | Use coupon | |
|---|---|---|---|
| Limitless Life Nootropics | 15% | Compound1515% off | Source research-grade Hexarelin |
| Ascension Peptides | 20% + 10% lifetime | COMPOUNDGU10% off | Source research-grade Hexarelin |
| Apollo Peptide Sciences | 20% | — | Source research-grade Hexarelin |
| Peptide University | 15-25% | — | Source research-grade Hexarelin |
Affiliate link — we may earn a commission at no extra cost to you. Research compounds are for laboratory use only.
Limitless Life Nootropics — Hexarelin
Compound15Affiliate link — we may earn a commission at no extra cost to you. Research compounds are for laboratory use only.
Frequently Asked Questions
Frequently Asked Questions
-
Hexarelin is a synthetic hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) tagged a growth hormone secretagogue (GHS). Like other GHS compounds, it starts the ghrelin receptor (GHSR-1a) to push growth hormone release from the pituitary [PMID: 7957536]. What sets hexarelin apart is its extra grip to CD36, a scavenger receptor on cardiomyocytes. This CD36 grip brings heart care that works on its own from growth hormone [PMID: 10465272] — a trait ghrelin itself and most other synthetic secretagogues do not have.
-
Work shows hexarelin binds CD36 receptors on heart muscle cells, starting PKC signal work and lifting L-type calcium flow to make a positive inotropic effect [PMID: 10465272]. Preclinical work shows hexarelin holds heart cells from cell death set by angiotensin II, doxorubicin, and blood cut-and-restore hurt. It also cuts heart scar and holds back plaque build [PMC4178518]. A test in post-MI models showed better heart function, with more ejection fraction [PMID: 10614623]. Key point: these heart effects are GH-free — they come through direct CD36 grip, not from growth hormone rise.
-
Human phase I data from an IV dose test used bolus shots of 0.5, 1, and 2 mcg/kg, and showed clear, dose-based GH release at all doses [PMID: 7957536]. Tales of under-skin use tell of 200 mcg each shot, given one to three times a day — though these lack clinic back. Animal tests have run under-skin shots of 100 to 300 mcg/kg/day [PMID: 7910650]. The short half-life of about 55 to 71 minutes means the compound clears fast, which has real say for shot rate.
-
Hexarelin is tagged a research chemical in the United States, European Union, and United Kingdom. It is not okay for human use, medical check, or care use by the FDA, EMA, or MHRA. Rules bar the compound to lab research spots with qualified researchers and set test plans. It cannot be sold as a food pill, drug, or home good. Any one who wants the rule frame for hexarelin should see the full legal notes and guide at compoundguide.org/disclaimer.
Related Pages
- muscle growth
- growth hormone peptides
- anti aging
- GHK-Cu
Skin regeneration & collagen synthesis
- Semax
ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance
- Epitalon
Pineal peptide studied for telomerase activation and longevity